Metadata
- Name
- Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT04991870
- Description
- This phase I trial is to find out the best dose, possible benefits and/or side effects of
engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood
[CB]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back
(recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may
help to control the disease. - Data or Study Types
- clinical trial
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2021
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT04991870
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT04991870